AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01980316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
Study NCT01980316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-argatroban treated group
Description: Patients in control group will receive Unfractionated heparin treatment
Study NCT03352219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reality Check
Study NCT03352219 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity Attention Control
Study NCT04268784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Single and repeating oral dose(s)
Study NCT04268784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and repeating oral dose(s)
Study NCT04000906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 10.5 mg/m2
Study NCT01094873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection
Study NCT02707055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Ghrelin Receptor Inverse Agonist
Study NCT02707055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-05190457
Description: Ghrelin Receptor Inverse Agonist
Study NCT02707055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02707055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02794493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Formula LC09
Study NCT02794493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04433169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans Retinoic Acid
Description: ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
Study NCT04433169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGFR inhibitor
Description: VEGFR inhibitor
Study NCT04433169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: chemotherapy
Study NCT04367168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Study NCT04367168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Study NCT03556657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
Study NCT00736242 — intervention group
Intervention type: BIOLOGICAL
Intervention: PEG-IFN alfa-2b
Description: Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
Study NCT00736242 — intervention group
Intervention type: DRUG
Intervention: RBV
Description: Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
Study NCT02942199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx
Description: The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study NCT01448746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: 40mg 12 hours before surgery and 12 hours later surgery
Study NCT04502329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Energy Restriction Intermittent Fasting Diet
Study NCT01273831 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: atracurium
Description: atracurium, Drop,0.5 mg/kg, one time, one day
Study NCT01273831 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisatracurium
Description: cisatracurium, drop,0.15mg/kg,one time, one day
Study NCT02359669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StimuLearn Intervention
Description: * StimuLearn apps~* Cognitive questionnaires
Study NCT02359669 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Without StimuLearn intervention
Description: Cognitive Questionnaires
Study NCT03365765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet
Study NCT03365765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin Intravenous
Study NCT03365765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin Intravenous
Study NCT03365765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil Intravenous
Study NCT03365765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil Intravenous
Study NCT03087591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03087591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
Description: Given IV
Study NCT02007486 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
Study NCT01415505 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol, Valsartan and Hydrochlorothiazide
Description: Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Study NCT03431077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
Study NCT00991926 — intervention group
Intervention type: DRUG
Intervention: Orlistat
Description: orlistat (Xenical, Roche, UK)120 mg tid
Study NCT00991926 — intervention group
Intervention type: OTHER
Intervention: normo-caloric diet
Description: Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
Study NCT01627392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Description: 6 hour smoking abstinence
Study NCT01006044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells
Description: Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
Study NCT02621606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-6884
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884
Study NCT01094873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection
Study NCT02011802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algosteril TM
Study NCT02011802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbact TM
Study NCT01796041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Study NCT02584205 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Powerbreathe
Description: In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea.
Study NCT02584205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe
Description: In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea.
Study NCT02048384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin alone (Arm A)
Description: metformin alone
Study NCT02048384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin (Arm B)
Description: rapamycin + metformin
Study NCT02048384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin (Arm B)
Description: rapamycin + metformin
Study NCT02692248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
Study NCT02692248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV day 1 during 4 cycles.
Study NCT02692248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
Study NCT02692248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
Study NCT02692248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
Study NCT03112044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg)
Description: Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
Study NCT03112044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Lung Perfusion (EVLP)
Description: Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
Study NCT01826968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment maneuver
Description: In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
Study NCT03512067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients given EMV Ventilation
Description: Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
Study NCT02039505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion
Study NCT02039505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo
Study NCT02039505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo
Study NCT00761501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: Oral
Study NCT00761501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen (Proxen S)
Description: Oral
Study NCT00761501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen (Naprosyn E)
Description: Oral
Study NCT04476017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral tablets.
Study NCT01366833 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
Study NCT01366833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent insertion
Description: After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
Study NCT00004010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Study NCT00004010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD regimen
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study NCT00004010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00004010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03636152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI carotid
Description: To assess the carotid atherosclerotic plaques
Study NCT02199834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: 15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
Study NCT02199834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback report
Description: Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
Study NCT02199834 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized feedback report
Description: Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
Study NCT03636152 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI carotid
Description: To assess the carotid atherosclerotic plaques
Study NCT01714414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Study NCT01714414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Study NCT03636152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APWV
Description: Doppler measurement of the APWV
Study NCT03636152 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: APWV
Description: Doppler measurement of the APWV
Study NCT03636152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active Drug
Study NCT03636152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo for the control group.
Study NCT01836692 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy treatment
Description: Intensity Modulated Radiotherapy treatment
Study NCT02270346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study NCT02270346 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study NCT01664845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 500mg tid
Study NCT01664845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegylated-IFN
Description: pegasys 180 mcg qw
Study NCT01664845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated-IFN
Description: pegasys 180 mcg qw
Study NCT01664845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800-1200 mg qd according to BW
Study NCT01664845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800-1200 mg qd according to BW
Study NCT00836823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Alfuzosin 10mg once daily for 12 months
Study NCT01998373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training leaflet and oral training
Description: The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
Study NCT03145116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT ASPHINA 509
Description: Intraocular lens
Study NCT01714414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Study NCT01714414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV